Efficacy of Intermediate and High Intensity Regimens in Patients With Relapsed Acute Lymphoblastic Leukemia
NCT ID: NCT04699162
Last Updated: 2021-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
56 participants
OBSERVATIONAL
2016-07-01
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
First Report, Five Years Experience of the Acute Leukemia Work Group
NCT02990104
Overweight and Obesity as Prognostic Factors for Survival in Children With Acute Lymphoblastic Leukemia
NCT04271215
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD
NCT05137860
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
NCT00084916
Metformin Reduce the Relapse Rate on Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic Leukemia
NCT03118128
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Age over 60 years
15 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Christian Omar Ramos-Peñafiel, MD, PhD
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Christian Omar Ramos-Peñafiel, MD, PhD
Head of the hematology hospitalization area
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christian O Ramos-Peñafiel, MD, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Hospital General de México Dr. Eduardo Liceaga
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Regional de Alta Especialidad de Ixtapaluca
Ixtapaluca, State of Mexico, Mexico
Hospital General de México "Dr. Eduardo Liceaga"
Mexico City, , Mexico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DECS/JPO-CT-397-2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.